Small cell lung cancer: Clinical Practice Guidelines in Oncology™

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 6, 2006, Pages 602-622

  Johnson, Bruce E ^a   Crawford, Jeffrey ^b   Downey, Robert J ^c   Ettinger, David S ^d   Fossella, Frank ^e   Grecula, John C ^f   Jahan, Thierry ^g   Kalemkerian, Gregory P ^h   Kessinger, Anne ⁱ   Koczywas, Marianna ^j   Langer, Corey J ^k   Martins, Renato ^l   Marymont, Maryanne Hoffman ^m   Niell, Harvey B ⁿ   Ramnath, Nithya ^o   Robert, Francisco ^p   Williams Jr , Charles C ^q  

^a Dana Farber/Partners CancerCare   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

ⁱ NEBRASKA MEDICAL CENTER   (United States)

^j City of Hope Cancer Center   (United States)

^k FOX CHASE CANCER CENTER   (United States)

^l SEATTLE CANCER CARE ALLIANCE   (United States)

^m NORTHWESTERN UNIVERSITY   (United States)

ⁿ UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^o ROSWELL PARK CANCER INSTITUTE   (United States)

^p UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^q H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

more..

Author keywords

Carcinoma; Chemotherapy; Mediastinum; Metastases; NCCN Clinical Practice Guidelines; Pulmonary carcinogenesis; Radiotherapy; Small cell; Surgical resection; Targeted therapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; NAVELBINE; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; TOPOTECAN; VINCRISTINE;

AREA UNDER THE CURVE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN RADIOGRAPHY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CIGARETTE SMOKING; CLINICAL FEATURE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG POTENTIATION; ENVIRONMENTAL FACTOR; FEBRILE NEUTROPENIA; HEREDITY; HUMAN; LOBECTOMY; LUNG SMALL CELL CANCER; META ANALYSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT CARE; PROGNOSIS; PROPHYLAXIS; REVIEW; SALVAGE THERAPY; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY;

EID: 33747592358     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0050     Document Type: Review

References (76)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Simon G, Ginsberg RJ, Ruckdeschel JC. Small-cell lung cancer. Chest Surg Clin N Am 2001;11:165-188, ix.
3. Simon M, Argiris A, Murren JR. Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol 2004;49:119-133.
4. Johnson BE, Jänne PA. Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematol Oncol Clin North Am 2004;18:309-322.
5. Travis WD, Colby TV, Corrin B, et al. Histological typing of lung and pleural tumours. World Health Organization International Histological Classification of Tumours. Berlin: Springer-Verlag, 1999.
6. Galanis E, Frytak S, Lloyd RV. Extrapulmonary small cell carcinoma. Cancer 1997;79:1729-1736.
7. Remick SC, Ruckdeschel JC. Extrapulmonary and pulmonary small-cell carcinoma: tumor biology, therapy, and outcome. Med Pediatr Oncol 1992;20:89-99.
8. Johnson B, Whang-Peng J, Naylor S, et al. Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. J Natl Cancer lnst 1989;81:1223-1228.
9. Guinee DG Jr, Fishback NF, Koss MN, et al. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. Am J Clin Pathol 1994;102:406-414.
10. Meriney SD, Hulsizer SC, Lennon VA, et al. Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma. Ann Neurol 1996;40:739-749.
11. Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124:1138-1148.
12. Manley GT, Smitt PS, Dalmau J, et al. Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol 1995;38:102-110.
13. Delisle L, Boyer MJ, Warr D, et al. Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications. Arch Intern Med 1993;153:746-52.
14. Johnson BE, Chute JP, Rushin J, et al. A prospective study of patients with lung cancer and hyponatremia of malignancy. Am J Respir Crit Care Med 1997;156:1669-1678.
15. Albain KS, Crowley JJ, LeBlanc M, et al. Determinants of improved outcome in small cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990;8:1563-1574.
16. Yip D, Harper DG. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer 2000;28:173-185.
17. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-392.
18. Johnson BE. Management of small cell lung cancer. Clin Chest Med 2002;23(1):225-239.
19. Evans WK, Shepherd FA, Feld R, et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985;3:1471-1477.
20. Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002;20:4665-4672.
21. Bishop JF, Raghavan D, Stuart-Harris R, et al. Carboplatin (CB-DCA, JM-8) and VP-16-213 in previously untreated patients with small cell lung cancer. J Clin Oncol 1987;5:1574-1578.
22. Sklaros DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small cell lung cancer: a Hellenic Cooperative Oncology Group study. Ann Oncol 1994;5:601-607.
23. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
24. Hanna NH, Einhorn L, Sandler A, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage small cell lung cancer. J Clin Oncol 2005;23(16S-Part II):1094s.
25. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-1801.
26. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-1624.
27. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10:890-895.
28. Loehrer PJ, Ansari R, Oonin R, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995;13:2594-2599.
29. Pujol JL, Daures JP, Riviere A, et al. Etoposide plus cisplatin with or without the combination of 4′-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001;93:300-308.
30. Miyomoto H, Nakabayashi T, Isobe H, et al. A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology 1992;49:431-435.
31. Niell HB, Herndon JE, Miller AA, et al. Randomized phase III Intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small cell lung cancer: CALGB trial 9732. J Clin Oncol 2005;23:3752-3759.
32. Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593: A phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:2114-2122.
33. Goldie JH, Goldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-1733.
34. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J Natl Cancer Inst 1991;83:855-861.
35. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282-291.
36. Miles DW, Earl HM, Souhami RL, et al. Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer. J Clin Oncol 1991;9:280-285.
37. Murray N, Gelmon K, Shah A, et al. Potential for long-term survival in extensive stage small-cell lung cancer (ESCLC) with CODE chemotherapy and radiotherapy [abstract]. Lung Cancer 1994;11(suppl 1):99.
38. Sculier JP, Paesmans M, Bureau G, et al. Multiple drug weekly chemotherapy versus standard combination regimen in small cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol 1993;11:1858-1865.
39. Souhami RL, Rudd R, Ruiz de Elvira MC, et al. Randomized trial comparing weekly versus 3-week chemotherapy in small cell lung cancer: A Cancer Research Campaign trial. J Clin Oncol 1994;12:1806-1813.
40. Fukuoka M, Masuda N, Negoro S, et al. CODE chemotherapy with or without granulocyte colony stimulating factor in small cell lung cancer. Br J Cancer 1997;75:306-309.
41. Murray N, Livingston RB, Shepherd FA, et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an lntergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999;17:2300-2308.
42. Teicher BA. Preclinical models for high-dose therapy. In: Armitage JO, Antman KH, eds. High-dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells, 2nd edition. Baltimore: Williams and Wilkins, 1995:14-42.
43. Klasa RJ, Murray N, Coldman AJ. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 1991;9:499-508.
44. Cohen MH, Creaven PJ, Fossieck BE, et al. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 1977;61:349-354.
45. Johnson DH, Einhorn LH, Birch R, et al. A randomized comparison of high dose versus conventional dose cyclophosphamide, doxorubicin, and vincristine for extensive stage small cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1987;5:1731-1738.
46. Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994;12:2022-2034.
47. Arriagada R, Le Chevalier T, Pignon J-P, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993;329:1848-1852.
48. Thatcher N, Girling DJ, Hopwood P, et al. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council multicentre randomized trial. J Clin Oncol 2000;18:395-404.
49. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-170.
50. Hurria A, Kris MG. Management of lung cancer in older adults. CA Cancer J Clin 2003;53:325-341.
51. Medical Research Council Lung Cancer Working Party. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Lancet 1996;348:563-566.
52. Souhami RL, Spiro SG, Rudd RM, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997;89:577-580.
53. Neuhauer M, Schwartz J, Caracandas J, et al. Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastern Cooperative Oncology Group performance status of 2, or age 70 years or more. J Clin Oncol 2004;22:1872-1877.
54. Weesteel V, Murray N, Gelmon K, et al. New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen. J Clin Oncol 1998;16:1940-1947.
55. Okamoto H, Watanabe K, Nishiwaki Y, et al. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol 1999;17:3540-3545.
56. Matsui K, Masuda N, Yana T, et al. Carboplatin calculated with Chatelut's formula plus etoposide for elderly patients with small-cell lung cancer. Intern Med 2001;40:603-606.
57. Murray N, Grafton C, Shah A, et al. Abbreviated treatment for elderly, infirm, or non-compliant patients with limited-stage small-cell lung cancer. J Clin Oncol 1998;16:3323-3328.
58. Ettinger DS. New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer. Semin Oncol 2001;28:27-29.
59. Kelly K. New chemotherapy agents for small cell lung cancer. Chest 2000;117:156S-162S.
60. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001;19:1743-1749.
61. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054-3060.
62. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. J Clin Oncol 1993;11:336-344.
63. Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small cell lung cancer. J Clin Oncol 2004;22:4785-4793.
64. Turrisi AT, Glover DJ, Mason BA. A preliminary report: concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer. Int J Radiat Oncol Biol Phys 1988;15:183-187.
65. Turrisi AT III, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide [see comments]. N Engl J Med 1999;340:265-271.
66. Schild SE, Bonner JA, Shanahan TG, et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;59:943-951.
67. Arriagada R, Le Chevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995;87:183-190.
68. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Radiation Overview Collaborative Group. N Engl J Med 1999;341:476-484.
69. Rostad H, Naalsund A, Jacohsen R, et al. Small cell lung cancer in Norway. Should more patients have been offered surgical therapy? Eur J Cardiothorac Surg 2004;26:782-786.
70. Lad T, Piantadosi S, Thomas P, et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 1994;106:320-3233.
71. Inoue M, Miyoshi S, Yasumitsu T, et al. Surgical results for small cell lung cancer based on the new TNM staging system. Thoracic Surgery Study Group of Osaka University, Osaka, Japan. Ann Thorac Surg 2000;70:1615-1619.
72. Inoue M, Nakagawa K, Fujiwara K, et al. Results of preoperative mediastinoscopy for small cell lung cancer. Ann Thorac Surg 2000;70:1620-1623.
73. Tsuchiya R, Suzuki K, Ichinose Y, et al. Phase Il trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIA small cell lung cancer: The japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg 2005;129:977-983.
74. Brock MV, Hooker CM, SyphardJE, et al. Surgical resection of lim-ited disease small cell lung cancer in the new eta of platinum chemotherapy: its time has come. J Thorac Cardiovasc Surg 2005;129:64-72.
75. Videtic GMM, Stitt LW, Dar AR, et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 2003;21:1544-1549.
76. Johnson BE, Linnoila RI, Williams JP, et al. Risk of second aerodigestive cancers increases in patients who survive free of small cell lung cancer for more than 2 years. J Clin Oncol 1995;13:101-111.